• Pédiatre FMH
• Reconnaissance MEBEKO Juillet 2013
• Interne des hôpitaux de Toulouse et de Besançon
• Lauréate de la Faculté de Médecine de Toulouse
• D.I.U. en Neurologie Pédiatrique
• Compétence spécifique en Psychologie de l'enfant et de l'adolescent
• Qualification en Médecine Générale

• D.U. en Micronutrition et Nutrithérapie
• D.U. en Phytothérapie et Aromathérapie
• Certificat de Maîtrise en "Biostatistiques et modélisations"
• Certificat de Maîtrise en "Recherche clinique et épidémiologique"
• Formatrice Maître de stage et conférencière

Expérience

Formation

Comités et conseils d’administration

• UNITAID : Conseil d'administration (représentant la société civile). 2011-2014
• OMS : 'WHO Task Force for New Drug Policy Development for TB'. 2012-2013
• OMS : 'WHO TB Strategic and Technical Advisory Group'. 2009-2012
• OMS : Expert au groupe de travail intergouvernemental sur la sante publique, l'innovation et la propriété intellectuelle. 2006-2007

Publications

1. von Schoen-Angerer T, Goyert A, Vagedes J, Kiene H, Merckens H, Kienle GS. Case report: Disappearance of an advanced adenomatous colon polyp after intratumoral injection with Viscum album. J Gastrointestin Liver Dis. 2014 23(4):449-52
2. von Schoen-Angerer T, Wilkens J, Kienle GS, Kiene H, Vagedes J. High-dose Viscum album extract treatment in the prevention of recurrent bladder cancer: a retrospective case series. Submitted for publication
3. von Schoen-Angerer T, Madeleyn R, Kienle GS, Kiene H, Vagedes J. Viscum album in the treatment of a girl with refractory childhood absence epilepsy. J Child Neural 20014: pii: 0883073814541473.
4. Michaelis R, Andrews D, Reiter JM, von Schoen-Angerer T. Resolving cognitive dissonance by acquisition of self-organizational skills may decrease drug-resistant seizures - A case report. Epilepsy Behav Case Rep 2014 (2): 64-66
5. von Schoen-Angerer T. Learning all the lessons: Expanding access to malaria diagnosis and treatment. J Public Health Policy. 2013 Mar 28. doi: 10.1057 /jphp.2013.15
6. von Schoen-Angerer T, Cohn J, Swan T, Piot P. UNIT AID can address HCV /HIV co-infection. Lancet. 2013 Feb 23;381 (9867):628.
7. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T. Promotion of access to essential medicines for Non-Communicable Diseases: practical implications of the UN political declaration. Lancet. 2013 Feb 23;381(9867):680-9
8. Cohn J, von Schoen-Angerer T, Jambert E, Arreghini G, Childs M. When falsified medicines enter the supply chain: Description of an incident in Kenya and lessons learned for rapid response. J Pub Health Policy, 2012 Nov 22. doi: 10.1057 /jphp.2012.53
9. van Schoen-Angerer T, Ford N, Arkinstall J. Access to Medicines in Resource-Limited Settings: The End of a Golden Decade? Global Adv Health Med. 2012; 1 (1): 50-57
10. Ford N, Singh K, Cooke G, Mills EJ, van Schoen-Angerer T, Kamarulzaman, du Cros P. Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons from HIV/AIDS. Clin Infect Dis. 2012 May;54(10):1465-72
11. Moon S, Jambert E, Childs M, van Schoen-Angerer T. A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health. 2011 Oct 12;7(1 ):39.
12. Maher D, van Schoen-Angerer T, Cohn J. Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection. Int J Clin Pract. 2011 Aug;65(8):824-7.
13. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis. 2011 (4):259-60
14. Arkinstall J, Childs M, Menghaney L, Ford N, van Schoen-Angerer T. How European policies risk harming access to generic medicines. J Generic Medicines, 2011, 8 (1 ): 14-22
15. van Schoen-Angerer T. Putting patients above politics. Lancet. 2010 Oct 16;376(9749):1301-2.
16. Neely M, Decosterd L, Fayet A, Lee JS, Margot A, Kanani M, di lulio J, von Schoen-Angerer T, Jelliffe R, Calmy A. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010 Nov;54(11):4619-25.
17. Moon S, Perez Casas C, Kindermans JM, de Smet M, von Schoen-Angerer T. Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 2009 Jul 21;6(7):e1000106.
18. Calmy A, Pizzocolo C, Pizarro L, Brucker G, Murphy R, Katlama C et al; Strategies in Resource-Limited Settings Working Group. The marriage of science and optimized HIV care in resource-limited settings. AIDS. 2008 Nov 12;22(17):2227-30.
19. Roey J, van Schoen-Angerer T, Ford N, Calmy A. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today. 2008 Jul;13(13-14):601-5.
20. van Schoen-Angerer T, Shepherd S, Lokuge K, Mills C, Fournier C. Kwashiorkor and severe acute malnutrition in childhood. Lancet. 2008 May 24;371 (9626):1748-9.